(MYNZ) Update: Trading Near The Lower End Of Its 52-Week Range, This Nasdaq Idea Needs Full Focus
MYNZ could become a near term breakout target for several reasons.
Here's what you need to soak in...
First off, MYNZ is trading towards the lower end of its 52-week range which means there is a ton of upside potential towards previous highs.
And with a 52-week high over $17.00 and an average price target of $18.00, MYNZ could be extremely undervalued at the moment.
Now, I'm not saying that MYNZ is going to surge to either level this week, but the potential needs to be noted.
It also needs to be noted that MYNZ has a low float of fewer than 11Mn shares. That means volatility could take grip in a moment's notice on MYNZ.
The company also has news out this week. Check it out: Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
Take a moment now to look through my initial report below. Then get MYNZ at the top of your watch-list this second.
We've got a ton to go over, so dig in. This is going to take a minute.
When I delivered this past champ to your inboxes originally, it went absolutely bonkers.
Running an insane 200+% (approx.) in the short term, it turned into a stunning multi-dollar mover.
With its breakout potential starting to grow again, I brought it back to attention only to watch it pop another 30+% in a very little period of time.
And most recently when I brought it to your attention on December 5th after it closed at $7.80, it made a $1.00+ (14%) approximate move to a high of $8.95 the next day.
So when I saw it had 2 press releases out this week, a low float of fewer than 11Mn shares, an average analyst price target of $18.00, and key IP acquisition news in 2023, I realized it needed to be back on alert immediately.
For Thursday, March 2nd, there is only one Nasdaq profile to have on your watch-list:
*Mainz Biomed B.V. (MYNZ)*
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:
No. 1 - Low Float Volatility Could Be On Display Daily
No. 2 - Two Different Analysts Provide An Average Price Target Of $18
No. 3 - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone
No. 4 - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK)
No. 5 - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead
But more on those in a second...
About MYNZ: Early Identification Of Cancer Saves Lives
Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.
Developing market-ready molecular in-vitro diagnostics tests since 2010.
Their goal is to place effective solutions where they need to be… In your hands.
A Blockbuster Early Detection Test for Colorectal Cancer
Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.
Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.
U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.
Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.
Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.
Attractive Valuation: They believe their current valuation holds tremendous upside.